Dr. Martens (LON:DOCS) Insider Buys £151.11 in Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori purchased 219 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were purchased at an average price of GBX 69 per share, for a total transaction of £151.11.

Ije Nwokori also recently made the following trade(s):

• On Tuesday, January 13th, Ije Nwokori acquired 192 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 78 per share, for a total transaction of £149.76.
• On Thursday, December 11th, Ije Nwokori bought 197 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 76 per share, with a total value of £149.72.

Dr. Martens Trading Up 2.0%

DOCS opened at GBX 68.62 on Monday. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The stock’s 50 day moving average price is GBX 73.90 and its 200-day moving average price is GBX 82.19. Dr. Martens plc has a one year low of GBX 43.02 and a one year high of GBX 100.87. The stock has a market cap of £663.29 million, a price-to-earnings ratio of 40.37, a P/E/G ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last issued its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DOCS. Royal Bank Of Canada restated a “sector perform” rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research report on Tuesday, January 27th. Finally, Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.